Boceprevir Plus Peginterferon Alfa-2a/Ribavirin in Treatment-Naïve Hepatitis C Virus Genotype 1 Patients: International Phase IIIb/IV TriCo Trial
Conclusion
High SVR12 rates can be achieved with boceprevir plus peginterferon alfa-2a/ribavirin in treatment-naïve HCV genotype 1 patients, including patients with well-compensated cirrhosis. Treatment is well tolerated when label restrictions are taken into account.
Trial Registration Number
ClinicalTrials.gov Identifier: NCT01591460.
Funding
F. Hoffmann-La Roche Ltd.
Source: Infectious Diseases and Therapy - Category: Infectious Diseases Source Type: research
More News: Anemia | Cirrhosis | Hepatitis | Hepatitis C | Infectious Diseases | Pegasys | Study | Virology